NMN and NR for Mental Health and Mood: What the Clinical Evidence Actually Shows

The direct answer

NMN and NR reliably raise NAD+ levels in blood in human trials, and NAD+ biology is mechanistically tied to processes relevant to mood and cognition, including mitochondrial energy production, SIRT1-driven neuroplasticity signaling, and neuroinflammation. However, no published randomized controlled trial has tested NMN or NR in patients diagnosed with major depressive disorder or generalized anxiety disorder using a validated psychiatric outcome as the primary endpoint. The supporting evidence for a direct antidepressant or anxiolytic effect currently comes from animal models, not human trials, and should be described to patients as mechanistically plausible rather than clinically proven.

What NMN and NR actually are

NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are both precursor molecules in the NAD+ salvage pathway. NR is converted enzymatically to NMN, which is then converted to NAD+ (nicotinamide adenine dinucleotide), a coenzyme required for mitochondrial energy production, DNA repair, and sirtuin enzyme activity. Both are sold in the United States as oral dietary supplements, not as prescription drugs, and neither has an FDA-approved indication for any condition, psychiatric or otherwise. They are frequently confused with NAD+ itself (which is not well absorbed orally) and with other longevity-marketed compounds; readers should confirm which specific molecule and formulation a product contains before comparing trial data across brands.

Why NAD+ decline is relevant to brain function

The brain is one of the most metabolically active tissues in the body, and its neurons depend heavily on mitochondrial ATP production, which in turn depends on NAD+ as an electron carrier. Aging research has associated declining NAD+ availability with reduced mitochondrial efficiency, impaired DNA repair capacity, and increased low-grade inflammatory signaling in the central nervous system. These are broadly the same processes implicated in current biological models of depression, anxiety, and age-related cognitive decline.

Two NAD+-dependent enzyme systems are most often discussed in this context:

SIRT1, a deacetylase enzyme concentrated in brain regions involved in mood regulation such as the hippocampus and prefrontal cortex, has been shown in animal studies to influence expression of brain-derived neurotrophic factor (BDNF) and to suppress inflammatory signaling pathways. Falling NAD+ availability is associated with reduced SIRT1 activity in these models.

PARP-1, an enzyme activated by DNA damage and oxidative stress, consumes NAD+ as a substrate during repair. Chronic oxidative stress, of the kind associated with prolonged psychological stress, can drive PARP-1 activity high enough to meaningfully deplete the local NAD+ pool, which in turn further impairs mitochondrial function. This creates a plausible feedback loop between chronic stress and cellular NAD+ depletion, though this loop has been characterized mainly in animal and cell-culture models rather than in living human brain tissue.

Both mechanisms are well described in the cell biology and animal literature. Neither has been directly demonstrated to translate into a clinical mood benefit in human trials, and readers should treat mechanism as a rationale for research, not as proof of a treatment effect.

What human trials have actually measured

Human research on NMN and NR has focused primarily on metabolic and aging-related endpoints, with mood and cognition typically appearing as secondary or exploratory measures rather than the primary study question. Several points are worth being explicit about:

NAD+ repletion. Multiple controlled human trials have measured blood or muscle NAD+ levels before and after NMN or NR supplementation and found meaningful increases within a few weeks of daily dosing. This is the best-established human finding for either compound and is consistent across independent research groups.

Cognitive screening and fatigue. A small number of controlled trials in older adults have included cognitive screening tools (such as the Montreal Cognitive Assessment) or fatigue scales as secondary endpoints and reported improvements favoring the supplement arm. These are promising but limited signals: the trials are small, cognitive screening tools are not the same as diagnostic neuropsychological assessment, and independent replication with mood or psychiatric endpoints as the primary outcome has not been published.

Mood-adjacent questionnaires. At least one small trial has used a general mood-state questionnaire (of the type used in healthy-volunteer research, not a clinical depression or anxiety scale) as a secondary measure. Reported improvements in these instruments in healthy volunteers do not establish an effect in people with a diagnosed mood or anxiety disorder, and subscale-level findings in small trials are prone to false positives when multiple comparisons are not corrected for.

Sleep. A small pilot study using polysomnography has been described in secondary literature as showing modest improvements in sleep quality and REM duration with evening NMN dosing. The circadian rationale, that NAD+-dependent clock proteins regulate sleep architecture, is grounded in established chronobiology research, but the human sleep-outcome data itself is preliminary and needs replication.

None of the specific figures attached to these findings in earlier drafts of this material could be verified against a confirmed primary source at the time of this rewrite. Editors and clinical reviewers should locate and cite the exact trials (for example, work from groups studying NMN in prediabetic women, or NR trials from groups such as Baur, Sinclair, or Martens and colleagues) before any precise numeric claim (percentage NAD+ increase, point change on a cognitive scale, sample size) is published on this page. Until that verification is complete, this article intentionally avoids stating exact trial numbers.

Mechanisms proposed for anxiety specifically

Two mechanistic threads are commonly cited to argue that NAD+ precursors could help anxiety symptoms, and both remain in the animal-evidence tier:

The kynurenine pathway. Tryptophan metabolism can be shunted toward either serotonin production or the kynurenine pathway, which generates both a potentially neurotoxic metabolite (quinolinic acid) and a metabolite with NMDA receptor-antagonist properties (kynurenic acid). Chronic stress and inflammation are associated with a shift toward the more excitotoxic branch of this pathway in animal models. NMN and NR enter NAD+ biosynthesis downstream of this pathway and do not require tryptophan as a substrate, which is mechanistically interesting but has not been tested as an anxiety intervention in humans.

SIRT3 and mitochondrial antioxidant defense. Animal studies of chronic stress have linked reduced NAD+-dependent SIRT3 activity in the amygdala to increased mitochondrial oxidative stress and anxiety-like behavior in rodents. Supplementing NAD+ precursors in these animal models has reduced markers of oxidative stress and anxiety-like behavior on standard rodent anxiety tests. This line of evidence is entirely preclinical. No human trial has enrolled patients with an anxiety disorder to test NMN or NR against a validated anxiety scale.

Dosing and practical considerations

Human trials have studied a range of NMN and NR doses, generally from the low hundreds of milligrams per day up to roughly a gram or more per day in some tolerability studies. No dose-response relationship has been established specifically for brain, mood, or cognitive outcomes, and this article does not provide individualized dosing guidance. Anyone considering NMN or NR for a mental health concern should discuss dosing, duration, and monitoring with a clinician rather than relying on doses reported in unrelated metabolic trials.

Bioavailability differences between capsule, sublingual, and liposomal formulations have been reported in small pharmacokinetic studies, but comparative efficacy data for mood or cognitive outcomes across formulations does not exist. Formulation claims made by supplement manufacturers should be treated as marketing until supported by outcome data, not just blood-level data.

Safety considerations relevant to psychiatric patients

Across the published trials referenced in this literature, the most commonly reported side effects are mild gastrointestinal symptoms (nausea, loose stool) and flushing, generally at higher doses, and generally resolving within the first weeks of use. No serious adverse events have been reported in the trials described in the literature reviewed for this article.

One theoretical interaction is worth flagging for clinical review: because NAD+ precursors increase substrate available to PARP-1, there is a theoretical concern about interaction with PARP inhibitor cancer therapies (such as olaparib or niraparib), where flooding the NAD+ pool could in theory blunt drug effect. This is a mechanistic concern rather than a documented clinical interaction, and patients on PARP inhibitors should not start NMN or NR without discussing it with their oncology team.

No pharmacokinetic interaction between NMN or NR and standard psychiatric medications (SSRIs, SNRIs, benzodiazepines, lithium) has been documented in the literature reviewed here. Absence of documented interaction is not the same as proof of safety in combination, particularly for patients on lithium or other narrow-therapeutic-index psychiatric medications, who should involve their prescribing clinician before adding any supplement that affects mitochondrial or cellular metabolism.

NMN's regulatory status in the United States has been unsettled, with an open FDA review of its status as a dietary ingredient. This status can change and should be reconfirmed against current FDA guidance rather than assumed from this article. See the FDA's dietary supplement information pages for current status: https://www.fda.gov/food/dietary-supplements

What the evidence does not support

NMN and NR are not FDA-approved treatments for depression, anxiety, or any other psychiatric condition. No published human trial has enrolled patients meeting diagnostic criteria for major depressive disorder or generalized anxiety disorder and measured NMN or NR against a validated clinical outcome as the primary endpoint. The existing human data on mood-adjacent measures comes largely from healthy or older, non-psychiatric populations using secondary outcome measures, which limits how far the findings can be generalized to people with a diagnosed mood or anxiety disorder. Mechanistic and animal evidence, while genuinely informative for future research design, has a long history of failing to predict clinical psychiatric drug efficacy in humans, and should not be presented to patients as equivalent to clinical proof.

A decision framework for readers considering NMN or NR for mood or brain-related concerns

This framework is meant to help a reader (or a clinician counseling a patient) sort where NMN or NR realistically fits, based on the evidence tiers above. It is not a treatment protocol and does not replace individualized medical advice.

Step 1: What is the actual concern?

• Diagnosed major depressive disorder or generalized anxiety disorder, or symptoms severe enough to impair function → NMN/NR is not supported as a treatment. Evidence-based care (psychotherapy, an appropriately prescribed medication, or both) is the primary path. A supplement should not delay or replace this.
• Subclinical fatigue, mild low mood, or cognitive complaints not meeting diagnostic thresholds, in an otherwise medically stable adult → this is the population where the limited positive human signal (fatigue, cognitive screening scores) exists. A supervised trial may be reasonable to discuss with a clinician.
• Sleep quality complaints → mechanistic rationale exists (circadian NAD+ biology) but human sleep-outcome data is preliminary; treat as low-confidence.

Step 2: Are there contraindication flags?

• Currently on a PARP inhibitor → do not start without oncology input.
• On lithium or another narrow-therapeutic-index psychiatric medication → involve the prescribing clinician first.
• Pregnant, breastfeeding, or under 18 → data is essentially absent; do not extrapolate adult trial findings.

Step 3: If proceeding, what would count as a real signal versus wishful thinking?

• Pick one or two objective or validated measures before starting (for example, a fatigue scale or sleep diary), not just subjective impression.
• Set a defined trial period (many of the relevant human trials ran 8 to 12 weeks) and a defined stopping rule if no change is seen.
• Do not layer in other new supplements or lifestyle changes simultaneously, or it becomes impossible to attribute any change.

Step 4: What should trigger stopping and seeking care instead of continuing?

• Worsening mood, new suicidal thinking, escalating anxiety, or new physical symptoms at any point → stop the supplement and seek clinical evaluation; these are not supplement side effects to "wait out."
• No change at all after the defined trial period → discontinue; continuing indefinitely without benefit is not evidence-based practice.

NMN versus NR for brain-related goals

Both compounds raise NAD+ through the same downstream pathway, entering at different points (NR is converted to NMN before proceeding to NAD+). Human pharmacokinetic data suggest both raise blood NAD+ to broadly similar degrees at comparable doses, though direct head-to-head trials with a brain or mood primary endpoint have not been published. NR has a longer commercial and research history and a larger existing body of human trial data overall; NMN has somewhat more animal-model data specific to neurological endpoints. Neither advantage translates into demonstrated superiority for mood or cognitive outcomes in humans. Choice between them is currently a matter of cost, formulation, and tolerability rather than proven mental health benefit.

Evidence boundary: what is established, what is plausible, what is not established

Established in humans: NMN and NR supplementation raises blood and tissue NAD+ levels in controlled trials. Both are generally well tolerated over trial periods of weeks to a few months, with mild gastrointestinal effects being the most common complaint.

Plausible but not established in humans: That raising NAD+ improves mood, reduces anxiety symptoms, or meaningfully improves cognition beyond what has been shown on secondary screening measures in small trials. That circadian or sleep benefits seen in a small pilot study will replicate in larger, adequately powered trials.

Not established: That NMN or NR treats major depressive disorder, generalized anxiety disorder, or any other diagnosed psychiatric condition. That any specific dose optimizes a brain or mood outcome. That NMN and NR differ meaningfully from each other in mental health effect.

When to seek care instead of trying a supplement

Persistent low mood, anxiety that interferes with daily functioning, sleep disruption lasting more than a few weeks, or any new suicidal thinking warrants evaluation by a primary care clinician, psychiatrist, or therapist rather than a trial of an unregulated supplement. NMN and NR have not been tested as treatments for these conditions, and delaying evidence-based care to try a supplement carries real risk.

A note on sourcing: the primary literature search conducted for this rewrite did not return a verified set of papers that could be confidently matched to the specific numeric claims in the original version of this article (exact percentage NAD+ increases, exact point changes on cognitive or mood scales, specific sample sizes). Rather than publish precise figures attached to the wrong or unverifiable source, this draft describes directional findings in general terms and flags them for the clinical reviewer to locate and cite the correct primary trials before publication. Any numeric claim reinstated in a future version should be checked directly against the named trial's published results, not carried forward from a prior draft.